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Abstract: Cancer vaccines have always been in the scope of gene therapy research. One of the most successful approaches 
has been working with genetically modiﬁ  ed tumor cells. However, to become a clinical reality, tumor cells must suffer a 
long and risky process from the extraction from the patient to the reimplantation as a vaccine. In this work, we explain our 
group’s approach to reduce the cell number required to achieve an immune response against a melanoma murine model, 
employing bead-selected B16 tumor cells expressing GM-CSF and B7.2.
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Introduction
Genetically modiﬁ  ed tumor cells are a very interesting approach with high potential in the ﬁ  eld of 
cancer vaccines (Dunussi-Joannopoulos et al. 1998; Kim et al. 2000; Mastrangelo and Lattime, 2002). 
In order to ﬁ  ght any type of cancer, the most reasonable strategy seems to be the use of the same 
tumor cells that we want to eliminate. Indeed, the transfection of these cells with immune-stimulating 
molecules as the cytokine GM-CSF (granulocyte and macrophage colony stimulating factor) has also 
been employed (Dunussi-Joannopoulos et al. 1998; Jaffee et al. 1998; Shi et al. 1999; Borrello and 
Pardoll, 2002; Moret-Tatay et al. 2003; Seraﬁ  ni et al. 2004; Herrero et al. 2006; Moret-Tatay et al. 
2006). However the signalling pathways of the immune system are very complex and in the last few 
years many studies have tested different combinations of cytokines with other molecules in order to 
improve antigen presentation, as for instance the membrane surface costimulatory molecule B7.2 
(Chong et al. 1998; Kim, 2001; Mukherjee et al. 2001; Parney et al. 2002; Zajac et al. 2003; 
Pizzoferrato, 2004).
Working with autologous tumor cells to prepare an antitumor vaccine is quite a difﬁ  cult task, since 
usually there are several critical stages to overcome: extracting cells from the patient, genetically 
modifying the cells, keep them in culture safely and expand them to the desired amount to ensure suf-
ﬁ  cient antigen and transgene for the treatment to work. For all these reasons, minimizing the quantity 
of tumor cells required in cancer vaccines is a great challenge (Farray and Clark, 2006; Herrero et al. 
2006; Copier et al. 2007; Herrero et al. 2008).
In this technical note we describe the tumor cell vaccine approach of our group employing 
magnetic bead selection of nonviral transfected tumor cells. We have previously achieved total 
survival of B16 melanoma-bearing mice in a preventive vaccine model using freshly GM-CSF 
transfected (non-selected) B16 cells (Moret-Tatay et al. 2003; Herrero et al. 2006; Herrero et al. 
2008). Now we wanted to take advantage of the fact that membrane surface B7.2 molecule has 
also already demonstrated its usefulness in some antitumor vaccine models. We therefore trans-
fected B16 cells with a bicistronic plasmid containing both m-gmcsf and m-B7.2 genes. Thus, we 
expect that the truly transfected cells, expressing B7.2 on their surface, would also express GM-
CSF. This would allow bead selection of the B7.2 transfected cells from the heterogeneous popu-
lation of transfected and non-transfected cells following a usual transfection procedure. With this 
new approach, we could study the possibility of reducing the number of cells required for a suc-
cessful antitumor vaccine.258
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Materials and Methods
Plasmids
The p2F m-gmcsf+m-B7.2 plasmid was derived 
from the pVITRO2 base plasmid (Invivogen, 
Toulouse, France), with the m-gmcsf plus m-B7.2 
genes. pVITRO2 allows the coexpression of 
two genes and contains two human ferritin 
composite promoters, FerH (heavy chain) and 
FerL (light chain), combined to the SV40 and 
CMV enhancers respectively, and the resistance 
gene to hygromycin.
All plasmids were ampliﬁ  ed in Escherichia coli 
DH5α, in selective LB broth (Pronadisa, Madrid, 
Spain) and extracted with the Qiagen Giga Endo-
free kit (Izasa SA, Barcelona, Spain), quantiﬁ  ed 
by spectrophotometry and tested by electrophore-
sis to conﬁ  rm their integrity and purity.
Cells and transfection procedure
B16 murine melanoma cells have been used in all 
of the experiments. These cells are syngeneic with 
the animals used for vaccination, i.e. C57BL/6 
mice (Harlan, Gannat, France).
B16 cells are adherent cells that are grown in 
ﬂ  asks with DMEM (Dulbecco’s modiﬁ  ed Eagle’s 
medium) (Sigma, Madrid, Spain), supplemented 
with 10% heat inactivated fetal bovine serum 
(FBS) (Biomedia, Boussens, France), penicillin 
(100 U/ml) and streptomycin (100 µg/ml). The 
cells are cultured in a humidiﬁ  ed incubator with 
5% CO2 at 37 ºC, and are detached from the ﬂ  asks 
with Trypsin-EDTA.
Lewis lung carcinoma, 3LL, cells were also 
employed, cultured under the same conditions as 
described.
The B16 cells employed for the vaccines were 
transfected by means of a chemical procedure 
based on PEI 25 KDa (polyethyleneimine. Sigma, 
Madrid, Spain) polyplexes (DNA:PEI, 1:1.41) with 
20 µg/ml p2F plasmids, as previously described 
(Moret-Tatay et al. 2003; Guillem and Aliño, 2004; 
Herrero et al. 2006; Moret-Tatay et al. 2006). The 
transfection percentage with this method lies 
between 20%–40% of total cells (data not shown), 
as observed using the reporter EGFP gene. Cells 
were transfected when more than 80% conﬂ  uence 
was reached in their ﬂ  asks. Tumor cells were 
irradiated 72 hours post-transfection with 150 
Gy, and then frozen in DMSO 5% in FBS and kept 
at −80 or −150 ºC until use.
3LL cells employed as vaccine were irradiated 
with 50 Gy dose.
ELISA of m-GMCSF
GM-CSF production of the transfected B16 cells is 
determined by Enzyme Linked Immunosorbent 
Assay (ELISA), performed on supernatant samples 
of the culture media taken 72 hours post-transfection 
and prior to cell detachment and irradiation, having 
changed the media every 24 hours. The BD OptEIA 
ELISA kit for m-GMCSF (Pharmingen, BD 
Biosciences, Madrid, Spain) was used. The time-
point of 72 hours was chosen on the basis of prior 
experimental results, assessed to study cytokine 
production over time, and using the referred 
transfection conditions (Moret-Tatay et al. 2003; 
Guillem and Aliño, 2004; Herrero et al. 2006; Moret-
Tatay et al. 2006), in order to achieve adequate 
production according to the literature (Borrello and 
Pardoll, 2002, Seraﬁ  ni et al. 2004).
Cytometry of m-B7.2 expression
Flow cytometry was performed to conﬁ  rm the 
presence of m-B7.2 on the surface of the transfected 
cells. At 72 h post-transfection, cells were harvested 
and pelleted in aliquots of 500,000 cells, washed 
and incubated in ice for at least 30 min. in 200 µl 
PBS-FBS (2.5%) -azide (0.01%) solution of 
primary antibody (1 µg/million cells of biotin-
conjugated rat anti-mouse CD86 monoclonal 
antibody (Pharmingen, BD, Madrid, Spain). Then, 
cells were washed twice in 1 ml PBS-azide and 
incubated in ice and darkness with the secondary 
antibody (0.5 µg/million cells): Streptavidin-
Fluorescein Isothiocyanate Conjugate (FITC) 
(Pharmingen, BD, Madrid, Spain).
Finally, cells were washed twice and resus-
pended in 500 µl PBS to be passed through the 
cytometer (Coulter Epics, XL; Beckman Coulter, 
Madrid, Spain) in order to analyze ﬂ  uorescence in 
the populations, to discriminate the truly trans-
fected cells. To avoid considering autoﬂ  uorescence 
or nonspeciﬁ  c binding as positive results, several 
controls were tested. The groups were: a) non-
transfected wild type B16 cells, without any anti-
body; b) non-transfected wild type B16 cells 
incubated with both antibodies; c) B16-p2F 
m-gmcsf + m-B7.2 transfected cells, without any 
antibody; d) B16-p2F m-gmcsf + m-B7.2 trans-
fected cells, incubated only with primary antibody; 
e) B16-p2F m-gmcsf + m-B7.2 transfected cells, 259
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incubated only with secondary antibody; and 
ﬁ  nally f) B16-p2F m-gmcsf + m-B7.2 transfected 
cells, incubated with both primary and secondary 
antibody.
Bead selection and puriﬁ  cation 
of transfected cells
This process is carried out by means of the 
Automacs device for magnetic cell separation 
(Miltenyi Biotec, Madrid, Spain), according to the 
manufacturer’s instructions and employing the 
Automacs columns. At 72 h post-transfection, cells 
are harvested and the Streptavidin Microbeads 
protocol is then followed (Miltenyi Biotec, 
Madrid, Spain). Brieﬂ  y, cells are incubated with 
the primary biotinylated antibody, as described for 
ﬂ  ow cytometry. Then, cells are incubated with 
streptavidin magnetic beads, as secondary anti-
body and finally they are passed through the 
Automacs column, using “Posseld 2” program, 
which gives us two eluted fractions, one contain-
ing the transfected cells, expressing B7.2 on their 
surface and thus also GM-CSF, and the other 
containing the non-transfected cells. Lastly, posi-
tive cells are counted and frozen until the time of 
the vaccination experiments.
Vaccination procedure
C57BL/6 mice (8–10 weeks old) kept under stan-
dard laboratory conditions were housed 5 mice per 
cage. All the experiments were approved by the 
Biological Research Committee of the University 
of Valencia (Valencia, Spain). In all cases, mice 
were vaccinated (right leg) with a single dose per 
week, in weeks −3, −1 and +1 (days −21, −7 
and +7), with respect to tumor injection (day 0) 
with 10
5 wild type B16 cells in the left leg or 10
5 
wild type 3LL cells, where indicated.
The number of cells employed in each vaccine 
dose represented only the truly transfected cells 
of previous experiments with non-selected cells, 
where total survival of the treated animals was 
achieved (Moret-Tatay et al. 2003; Herrero et al. 
2006; Herrero et al. 2008). Thus, we had to vac-
cine only with 20% of the previous doses (this 
being our expected percentage of truly transfected 
cells in that case). This meant vaccinating with 
40.000 selected cells per mouse, per dose, in 
100 µl DMEM. We also vaccinated with the 
double dose, 80.000 selected cells, and since this 
was still a reduced number of cells, we took the 
opportunity of exploring how these cells would 
work in a model where another type of tumor cells 
constituted the real target and B16 were just the 
bystander cytokine-producing cells. To this effect, 
we vaccinated with 80.000 B16 selected cells + 
320.000 3LL cells.
In all vaccination experiments, blood samples 
were taken from all the animals, pooling blood 
from the animals from the same group at each 
time-point. The samples were taken on days −22 
(before any manipulation of the animals, serving 
as base level or control in each group), −1 (the 
day before tumor implantation), and +15 (one 
week after the third and last dose was 
administered). Plasma was obtained by centrifu-
gation at 3000 rpm for 5 min. and kept at −20 ºC 
until use.
Tumor growth measurement 
and survival
Tumor growth in mice was monitored visually and 
measured with a caliper in two dimensions: A, the 
long diameter and B, the short diameter. Tumor 
volume was calculated with the formula 
V = (A × B
2)/2, and expressed in mm
3. Animals 
were collected at their death date to construct the 
survival curves.
Speciﬁ  c anti-TMP IgG ELISA
Measurement of IgG and IgG1 and IgG2a subclass 
antibodies to TMP (Tumor Membrane Proteins) 
was performed in serum samples by specific 
ELISA, as previously described (Herrero et al. 
2006; Herrero et al. 2008). TMP is an extract of 
the hydrophilic membrane proteins of the irradi-
ated B16 cells; thus, so with this ELISA, we test 
the speciﬁ  c response to our vaccine treatment, 
discarding any other non-specific immune 
responses (Bordier, 1981; Herrero et al. 2006; 
Herrero et al. 2008).
Plates were coated by overnight incubation of 
TMP at 0.8 µg/ml in carbonate buffer, pH 9.6. The 
next day, plates were neutralized with 1% BSA 
solution before addition of serum samples. For 
analysis, sera were diluted in dilution buffer (PBS-
BSA 1%-Tween 20 0.1%) at 1/1000 for total IgG 
and IgG1 subclass and at 1/100 for IgG2a. Bound 
antibodies were detected with goat antisera to total 
IgG (Biocheck, Foster City, USA) at 1/10000 or 
mouse IgG subclasses at 1/1000 (Sigma, Mouse 
monoclonal isotyping reagents, Madrid, Spain), 260
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followed by 1/5000 dilution of biotinylated rabbit 
antiserum to goat IgG (Sigma, Madrid, Spain) and 
streptavidin coupled to horseradish peroxidase 
(Sigma, Madrid, Spain). Plates were developed 
with a mixture of orthophenylenediamine (OPD, 
Sigma, Madrid, Spain) and hydrogen peroxide 
(Fluka-Sigma, Madrid, Spain), and read at 492 nm. 
All samples were assayed in duplicate, allowing 
estimation of mean OD value and standard 
deviation.
Statistical analysis
To statistically compare the results of tumor growth 
inhibition in the different treatment groups, a two-
way ANOVA was employed, with Bonferroni post 
hoc testing (95% conﬁ  dence interval, 95%CI), 
expressing statistically signiﬁ  cant differences on 
the basis of P  0.05, P  0.01 and P  0.001. The 
same test was applied to the results of ELISA 
assays.
For survival significance, we used the 
Kaplan-Meier survival curves and logrank non-
parametric test.
All the tests and graphs were performed with 
Graph Pad Prism 4 software®.
Results
Determination of m-B7.2 production
The strategies for the detection of B7.2 expression 
are illustrated in Figure 1. We employed a biotinylated 
anti-B7.2 antibody as the ﬁ  rst step for two kinds of 
experiments: ﬁ  rst, to check the transfection efﬁ  cacy 
by flow cytometry, using streptavidin-FITC as 
second step; second, to separate the positive 
(transfected) cells by magnetic beads selection, 
using streptavidin beads.
The efﬁ  ciency of m-B7.2 expression on B16 
cell surface, 72 h after transfection, was evaluated 
by ﬂ  ow cytometry. The results are summarized in 
Figure 2, which plots counts (Y) versus ﬂ  uorescence 
(X), and where we can identify speciﬁ  c surface 
expression of m-B7.2 in the right peak of the ﬁ  gure, 
whereas the middle and left peaks correspond to 
the transfected and non-transfected control cells, 
respectively.
The right area of the right peak, beyond the 
intersection with the middle peak, represents the 
proportion of transfected cells that are also ﬂ  uo-
rescent, i.e. the cells that express m-B7.2 on their 
surface. This area is approximately 40%–50% of 
the right peak, which was our expected transfection 
efﬁ  cacy, according to our previous experiments 
(data not shown).
Puriﬁ  cation of transfected cells 
by means of magnetic beads
As explained above, 72 h after transfection with 
p2F m-gmcsf + m-B7.2, the cells were incubated 
with biotinylated anti-B7.2 and later with strepta-
vidin beads, according to the manufacturer’s pro-
tocol. The selected cells also produced GM-CSF, 
as tested by ELISA, approximately ranging from 
90 to 175 ng/10
6 cells.
B7.2
Anti-B7.2
Biotinilated
Streptavidin-
Magnetic Bead
Streptavidin
-FITC
B16
transfected
Figure 1. Binding strategies to B7.2. B16 cells transfected with the 
plasmid p2F m-gmcsf+m-B7.2, will secrete GM-CSF into the medium 
and will also express B7.2 protein on their surface. The biotinylated 
anti-B7.2 antibody allows not only binding of the cells to streptavidin-
FITC to visualize them in cytometry assays, but also binding to 
streptavidin-magnetic beads, what let us separate these cells from 
the non-transfected ones.
Figure 2. Flow cytometry of B16 cells transfected with p2F 
m-gmcsf+mB7.2. The following B16 cell groups were passed through 
the cytometer and their graphs overlayed in a single one: a) B16 wild 
type cells, non-transfected and with no reagents incubation; and b) 
B16 wild type cells, non-transfected and with both the primary antibody 
and streptavidin-FITC. These two groups form the left peak. The 
central peak is formed by c) B16 transfected cells with p2F m-gmcsf 
+ m-B7.2, without the reagents incubation, d) B16 transfected cells 
with p2F m-gmcsf + m-B7.2, incubated only with the primary antibody 
and e) B16 transfected cells with p2F m-gmcsf + m-B7.2, only 
with streptavidin-FITC. Finally, f) B16 transfected cells with p2F 
m-gmcsf + m-B7.2, incubated with both primary antibody and 
streptavidin-FITC, corresponds to the right peak. The graph repre-
sents the green ﬂ  uorescence in X versus count number in Y.261
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The efﬁ  ciency of the transfected B16 cell puri-
ﬁ  cation is about 4% of the number of starting cells 
before transfection. From the 20%–40% of expected 
transfected cells, we purify 1/5 by this procedure.
Efﬁ  cacy of the antitumor vaccine with 
transfected and selected cells
According to our previous results, total survival of 
vaccinated animals was obtained with 200.000 
non-selected GM-CSF transfected cells. Now, hav-
ing puriﬁ  ed only the B7.2 and GM-CSF producing 
cells, we vaccinated with a cell dose representing 
only the expected truly transfected cells, i.e. 40.000 
cells (the equivalent of 20% of 200.000), per 
mouse, per dose. Moreover, we also vaccinated 
with the double number of cells (80.000) and, since 
this cell number was still quite reduced, we pre-
pared a mixture of 3LL irradiated cells plus the 
GMCSF+B7.2 -B16 producing cells to determine 
wether the procedure could also promote an efﬁ  -
cient 3LL antitumor immune response. The treat-
ment groups were: a) Control (100 µl DMEM), to 
challenge with B16 tumor; b) Control-bis (100 µl 
DMEM), to challenge with 3LL tumor; c) 
B16-GMCSF+B7.2/40, employing 40.000 B16 
selected cells per dose, in 100 µl DMEM; d) 
B16-GMCSF+B7.2/80, the same as before 
but with 80.000 B16 selected cells ; e) B16-
GMCSF+B7.2/80 + 3LL, each dose being 80.000 
B16 selected cells and 320.000 irradiated 3LL cells, 
with B16 tumor challenge; f) B16-GMCSF+B7.2/
80+3LL, the same as before but with 3LL tumor 
challenge.
The results of tumor growth inhibition are 
shown in Figure 3, for the groups with B16 tumor 
and in Figure 4, for the groups with 3LL tumor.
The three treatment groups of mice bearing 
B16 tumor were statistically different from the 
control, with differences equal or bigger than 
P  0.01 from day +17. The best B16 tumor 
inhibition was achieved by the B16-GM+B7.2/40 
group, with 90% tumor growth inhibition, versus 
the control group, on day +21. It is remarkable 
that no significant differences in tumor 
growth inhibition were observed between B16-
GM+B7.2/80 and B16-GM+B7.2/80 + 3LL 
groups, suggesting that adding a different type of 
tumor cell to a bystander cytokine-producing line, 
does not impair the results.
These observations also correlate with the sur-
vival curves, in Figure 5, where B16-GM+B7.2/40 
achieved the best survival results, doubling the 
survival period achieved by the control group, with 
a signiﬁ  cant difference of P = 0.0021 with the 
logrank test. Despite this, no total survival was 
obtained in any of the mice.
Interestingly, although the same tumor growth 
inhibition was obtained in both B16-GM+B7.2/80 
and B16-GM+B7.2/80+3LL groups, their survival 
curves show a differentiation of nearly 20 days 
delayed end-point in the group where no cell 
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Figure 3. B16 Tumor growth inhibition in the selected cells 
vaccine. Tumor growth inhibition vaccinating with the groups B16-
GM+B7.2/40, B16-GM+B7.2/80, B16-GM+B/.2/80 + 3LL and control. 
Tumor was implanted on day 0 with 10
5 B16 wild type cells in the left 
leg and vaccine doses were injected in the right leg on days −21, −7 
and +7. “a” represents P  0.001 and “b” P  0.01, versus control.
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Figure 4. 3LL Tumor growth inhibition in the selected cells 
vaccine. Employing the same procedure as in Figure 3, the preventive 
treatment B16-GM+B7.2/80+3LL (80.000 B16 selected cells + 320.000 
3LL irradiated cells) was evaluated versus control, challenging the 
mice on day 0 with 10
5 3LL wild type cells.“a” represents 
P  0.001 versus control.262
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mixture had been performed. B16-GM+B7.2/80 
achieved a significant difference of P = 0.005 
regarding Control group while B16-GM+B7.2/
80+3LL showed no statistical difference.
B16-GM+B7.2/40 and B16-GM+B7.2/80 do 
not show any statistical difference between 
them.
In the case of mice bearing 3LL tumor, the total 
time of survival was very short, 20 days maximum, 
since 3LL is a highly aggressive tumor. Although 
the treated group achieved significant tumor 
growth inhibition with P  0.001 from day +10, 
versus its control, the volume reduction was about 
20% maximum, which was not enough to diferen-
tiate the survival curves of the two groups (data 
not shown).
Speciﬁ  c anti-TMP IgG production
The ﬁ  ndings from the anti-TMP ELISA studies in 
measuring speciﬁ  c total IgG production are sum-
marized in Figure 6-A, for results in the B16 tumor 
groups and Figure 6-B, for 3LL tumor groups. In 
the total speciﬁ  c IgG studies, we always found 
higher productions in the treated groups compared 
with the controls. In the B16 tumor groups, there 
were no remarkable differences and all of them 
peaked on day +15. However, the group treated 
against 3LL showed its maximum on day −1. In 
all cases, the SD was less than 5% of the OD mean 
value, and therefore the SD is not appreciable in 
the graphs. After performing the two-way ANOVA 
test, all the treatments were statistically different 
from the Control group at days −1 and +15, with 
P  0.001.
The same results were observed in the IgG 
subtypes IgG1 (Fig. 7-A) and IgG2a (Fig. 7-B) 
analysis.
Discussion
Engineered cells secreting cytokines have demon-
strated to be a very interesting approach in cancer 
vaccines (Dunussi-Joannopoulos et al. 1998; Jaffee 
et al. 1998; Shi et al. 1999; Kim et al. 2000; 
Mastrangelo and Lattime, 2002; Borrello and 
Pardoll, 2002; Seraﬁ  ni et al. 2004), as we have also 
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Figure 5. Survival in the selected cells vaccine against B16 
tumor. With the death dates of the animals, survival curves were 
constructed with Kaplan-Meier method in the groups with B16 tumor: 
Control, B16-GM+B7.2/40, B16-GM+B7.2/80 and B16-GM+B7.2/
80+3LL. Logrank statistical test was performed and Pvalues are 
included were signiﬁ  cant difference was achieved regarding Control 
group.
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Figure 6. Total anti-TMP IgG. Blood was extracted from the tail vein 
on days −22, −1 and +15 regarding tumor implantation on day 0. 
ELISA assays were performed in the plasma obtained. Figure 6-A 
shows the results in the groups challenged with B16 tumor and 
Figure 6-B, those for 3LL tumor. The samples were analyzed by 
duplicate with representation of the mean OD and SD, though SD 
cannot be appreciated since it was very small. Two-way ANOVA was 
performed, *P  0.001.263
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seen (Moret-Tatay et al. 2003; Herrero et al. 2006; 
Moret-Tatay et al. 2006; Herrero et al. 2008), 
though we are aware of the great difﬁ  culty of work-
ing with this approach in actual clinical practice. 
In fact, tissue or cell samples from the patients 
must be kept in culture, ampliﬁ  ed to a larger num-
ber, transfected and then returned to the same 
patient. In this context, guaranteeing strict handling 
conditions for clinical use, an acceptable number 
of cells, as well as cytokine production, is not an 
easy task. This is why we decided to try to reduce 
the cell number required to start a proper immune 
response against the tumor, thus avoiding very 
complex cell work in future patients.
In our hands, the best results of preventive 
antitumor vaccines were obtained in a murine 
melanoma model with a vaccine dose of 2 × 10
5 
transfected cells. The vaccination protocol was 
exactly the same as described in this manuscript. 
With that vaccine we achieved 100% and 80% 
survival levels employing genetically modiﬁ  ed 
cells to produce mGM-CSF and mGMCSF+mB7.2, 
respectively. In those experiments we conﬁ  rmed 
two points, supported also by the ﬁ  ndings of other 
groups: 1) The idea that larger levels of GM-CSF 
production are not necessarily better (Borrello and 
Pardoll, 2002; Rodríguez-Lecompte et al. 2004; 
Seraﬁ  ni et al. 2004; Herrero et al. 2006) but are 
sometimes worse; and 2) There is some kind of 
synergistic effect between GM-CSF and B7.2. 
Thus, we knew that we did not really need an 
enormous quantity of GM-CSF, and that B7.2 also 
offered some advantages in several tumor vaccine 
models. Finally, we knew that only 20%–40% of 
our cells were really functional, because this was 
the true transfection efﬁ  cacy. Thus, the question 
is: Why not try a vaccine with only the truly 
transfected cells? Many efforts have been made 
in the course of gene therapy history to achieve 
transfection of the totality of the cells. However, 
to date this has been nearly impossible, particu-
larly when working with non-viral vectors, 
although the different methods have been greatly 
improved (i.e Amaxa’s Nucleofector). Our 
approach is not to enhance the transfection pro-
cess, but to isolate and purify the transfected cells 
that we obtain. We employed the Automacs (Milt-
enyi Biotec, Spain) to select our cells producing 
both GM-CSF and B7.2, using the magnetic 
streptavidin microbeads protocol.
Following this protocol, 72 h after cell transfec-
tion, we puriﬁ  ed 4% viable cells from the total cells 
that we started with. We think that this is quite a 
low yield, since the transfected cells are supposed 
to represent 20%–40% of the starting cells (Herrero 
et al. 2008). These results could be due to several 
reasons. On one hand, the whole puriﬁ  cation pro-
cess is time consuming (several hours), during 
which the cells probably suffer from not being in 
their appropriate culture conditions. This results in 
a dramatic drop in viability. Therefore, optimized 
protocol conditions for reducing the length of the 
process or the kind of selection protocol in the 
device would contribute to improve the cell selec-
tion yield. Another reason to take in consideration 
is that probably, our B7.2 cassette, which provides 
long term expression, is not really strong since the 
ﬂ  uorescence values in Figure 2 are not really high. 
Probably, using a more potent promoter could 
boost B7.2 expression and then easier cell recogni-
tion and separation in the Automacs would be 
achieved.
We studied two different puriﬁ  ed cell doses in 
a preventive vaccine model, 40.000 selected cells 
(20% of 2 × 10
5) and 80.000 selected cells 
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Figure 7. Anti-TMP IgG subtypes. In the same way as in Fig. 6, the 
plasma samples were tested with ELISA for IgG subtypes, IgG1 in 
Figure 7-A and IgG2a in Figure 7-B. Two-way ANOVA was performed, 
*P  0.001.264
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(40% of 2 × 10
5), in an attempt to reproduce the 
successful model that we achieved with preventive 
non-selected genetically modiﬁ  ed cells but this 
time employing only the number of truly trans-
fected cells that we expected to have in the previ-
ous assays. With this new approach, we reached a 
maximum of 90% tumor growth inhibition in the 
group treated with B16-GM+B7.2/40 against B16 
melanoma tumor. The groups treated with 
B16-GM+B7.2/80 and B16-GM+B7.2/80 + 3LL, 
contributing double dose of cell antigen, GM-CSF 
and B7.2, surprisingly only reached about 60% 
tumor growth inhibition. As other authors have 
pointed out (Borrello and Pardoll, 2002; Seraﬁ  ni 
et al. 2004), this suggests that here we probably 
have an excess of GM-CSF, which proves disad-
vantageous in our system. A vaccine assay explor-
ing dose-dependent effects of our selected cells 
would help us verify this point. Phenomena of 
immune suppression have been described in the 
last few years to explain results of this kind and 
the apparent paradoxical effect of certain cytokines 
as GM-CSF, that can act as immune activators or, 
contrarily, as suppressors of the immune response. 
This is most probably due to immune cells such as 
regulatory T cells (De Visser et al. 2006; Zou, 
2006) or the recently described Myeloid Derived 
Suppressor Cells (Seraﬁ  ni et al. 2004; Horna et al. 
2006; Seraﬁ  ni et al. 2006a, b). The survival results 
correlate with those of tumor growth inhibition: 
although no total survival was achieved, the best 
results were obtained with B16-GM+B7.2/40, 
doubling the survival period of the control group. 
The other two groups challenged with B16 tumor 
had different survival results despite similar tumor 
growth inhibitions. This could also be due to the 
suppressor phenomena that have been mentioned 
above, where the “extra” irradiated cells could be 
generating an extra immune response that impairs 
the action against B16 tumor.
We also wanted to take advantage of working 
with a reduced number of cells, to test a new pos-
sibility, that could be very interesting in the clini-
cal practice: mixing our transfected and puriﬁ  ed 
B16 cells, in the role of cytokine producers and 
non speciﬁ  c immune stimulants, with other differ-
ent cells, 3LL in this case, in the role of speciﬁ  c 
immunizing antigen, for combating a 3LL tumor. 
This ﬁ  rst approach could also be intended for other 
bystander cytokine producing non-tumor cells, as 
for instance ﬁ  broblasts, which would be easier to 
remove and reintroduce to a clinical patient. 
We achieved a significant tumor reduction 
(approximately 25%) in the treated group, though 
this was not good enough to elicit any kind of 
survival. 3LL tumor is a very aggressive and a 
rapidly progressing malignancy; as a result, by 
better adjusting the doses and times, we probably 
would obtain better results.
Regarding speciﬁ  c IgG productions, we always 
found higher levels in treated groups than in con-
trols, though interestingly, in the groups challenged 
with B16 tumor, which worked better, we recorded 
the highest values on day +15, while in groups 
challenged with 3LL tumor, which worked worse, 
the highest values appeared on day −1. Again, these 
results suggest a different kind of immunoglobulin 
switch and therefore, a different sequence of 
immune responses, resulting in very different rates 
of success (Herrero et al. 2006).
Although the overall results were not as good as 
those with the non-selected cells vaccine, no conclu-
sions can be drawn before a dose-dependent study 
is performed with these selected cells. It remains to 
be elucidated how synergistic effects between anti-
gens, GM-CSF and costimulatory B7.2 molecules 
cooperate in the generation of efﬁ  cient antitumor 
response or toxicity. We cannot exclude a lack of 
net antigen contribution due to the reduction in cell 
number or, contrarily, an excess in GM-CSF produc-
tion which could result in a loss of vaccine efﬁ  cacy. 
These experiments will focus our future attention, 
and will contribute to clarify the exact need for each 
component in a cell vaccine that could become suit-
able for use in clinical practice.
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